
Michael A Fischer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4638583/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Development of a measure of prescriber satisfaction with academic detailing: the PSAD. Drugs in Context, 2022, 11, 1-12.	2.2	2
2	Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System. Journal of General Internal Medicine, 2022, 37, 3562-3569.	2.6	7
3	A Comparison of Individuals with Diabetes and EMPA-REG Trial Participants: Exploring Aspects of External Validity. Journal of General Internal Medicine, 2022, , 1.	2.6	0
4	Getting to 100%: Research Priorities and Unanswered Questions to Inform the US Debate on Universal Health Insurance Coverage. Journal of General Internal Medicine, 2022, 37, 949-953.	2.6	1
5	Factors Associated With Opioid Overdose After an Initial Opioid Prescription. JAMA Network Open, 2022, 5, e2145691.	5.9	24
6	Opioid-related overdose and chronic use following an initial prescription of hydrocodone versus oxycodone. PLoS ONE, 2022, 17, e0266561.	2.5	2
7	Secondary Effects of an Opioid-Focused Academic Detailing Program on Non-Opioid Controlled Substance Prescribing in Primary Care. Substance Abuse, 2021, 42, 962-967.	2.3	1
8	Designing a Strategy Trial for the Management of Gout: The Use of a Modified Delphi Panel. ACR Open Rheumatology, 2021, 3, 341-348.	2.1	3
9	Association Between Patientâ€Clinician Relationships and Adherence to Antihypertensive Medications Among Black Adults: An Observational Study Design. Journal of the American Heart Association, 2021, 10, e019943.	3.7	18
10	Non-Visit-Based and Non-Infection-Related Antibiotic Use in the US: A Cohort Study of Privately Insured Patients During 2016–2018. Open Forum Infectious Diseases, 2021, 8, ofab412.	0.9	4
11	Educating community clinicians using principles of academic detailing in an evolving landscape. American Journal of Health-System Pharmacy, 2021, 78, 80-86.	1.0	8
12	Academic Detailing to Increase Prescribing of HIV Pre-exposure Prophylaxis. American Journal of Preventive Medicine, 2021, 61, S87-S97.	3.0	4
13	Influenza Vaccine Uptake in the Year After Concurrent vs Separate Influenza and Zoster Immunization. JAMA Network Open, 2021, 4, e2135362.	5.9	1
14	Examining the Drivers of Racial/Ethnic Disparities in Non-Adherence to Antihypertensive Medications and Mortality Due to Heart Disease and Stroke: A County-Level Analysis. International Journal of Environmental Research and Public Health, 2021, 18, 12702.	2.6	1
15	COVID-19-related adaptations to the implementation and evaluation of a clinic-based intervention designed to improve opioid safety. Drugs in Context, 2021, 10, 1-8.	2.2	2
16	Changes in Utilization of Generic Angiotensin Receptor Blockers Following Product Recalls in the United States. JAMA - Journal of the American Medical Association, 2020, 323, 87.	7.4	9
17	Structural and Social Determinants of Health Factors Associated with County-Level Variation in Non-Adherence to Antihypertensive Medication Treatment. International Journal of Environmental Research and Public Health, 2020, 17, 6684.	2.6	13
18	Comparative Risks of Cardiovascular Disease in Patients With Systemic Lupus Erythematosus, Diabetes Mellitus, and in General Medicaid Recipients. Arthritis Care and Research, 2020, 72, 1431-1439.	3.4	24

MICHAEL A FISCHER

#	Article	IF	CITATIONS
19	Identification of barriers to safe opioid prescribing in primary care: a qualitative analysis of field notes collected through academic detailing. British Journal of General Practice, 2020, 70, e589-e597.	1.4	12
20	Non-Infection-Related And Non-Visit-Based Antibiotic Prescribing Is Common Among Medicaid Patients. Health Affairs, 2020, 39, 280-288.	5.2	16
21	Risk of Incident Atrial Fibrillation With Zoledronic Acid Versus Denosumab: A Propensity Score–Matched Cohort Study. Journal of Bone and Mineral Research, 2020, 36, 52-60.	2.8	15
22	SUPPORT-AF II: Supporting Use of Anticoagulants Through Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e005871.	2.2	18
23	Racial/ethnic variation in stroke rates and risks among patients with systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 2019, 48, 840-846.	3.4	18
24	The Future of the Patient-Centered Outcomes Research Institute (PCORI). Journal of General Internal Medicine, 2019, 34, 2291-2292.	2.6	5
25	Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients. Seminars in Arthritis and Rheumatism, 2019, 49, 389-395.	3.4	22
26	Stepped-wedge randomised trial to evaluate population health intervention designed to increase appropriate anticoagulation in patients with atrial fibrillation. BMJ Quality and Safety, 2019, 28, 835-842.	3.7	13
27	Academic Detailing in the New Era of Diabetes Medication Management. Current Diabetes Reports, 2019, 19, 140.	4.2	3
28	Appropriateness of outpatient antibiotic prescribing among privately insured US patients: ICD-10-CM based cross sectional study. BMJ: British Medical Journal, 2019, 364, k5092.	2.3	166
29	Lipid Testing and Statin Prescriptions Among Medicaid Recipients With Systemic Lupus Erythematosus or Diabetes Mellitus and the General Medicaid Population. Arthritis Care and Research, 2019, 71, 104-115.	3.4	15
30	CS-19â€Heart failure hospitalizations among SLE and diabetes mellitus patients compared to the general U.S. medicaid population. , 2018, , .		0
31	Effect of a Remotely Delivered Tailored Multicomponent Approach to Enhance Medication Taking for Patients With Hyperlipidemia, Hypertension, and Diabetes. JAMA Internal Medicine, 2018, 178, 1182.	5.1	71
32	Changes in Outpatient Use of Antibiotics by Adults in the United States, 2006–2015. Drug Safety, 2018, 41, 1333-1342.	3.2	13
33	Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Amputation. JAMA Internal Medicine, 2018, 178, 1199.	5.1	3
34	Step Therapy—Clinical Algorithms, Legislation, and Optimal Prescribing. JAMA - Journal of the American Medical Association, 2017, 317, 801.	7.4	14
35	Restrictions of Hepatitis C Treatment for Substance-Using Medicaid Patients: Cost Versus Ethics. American Journal of Public Health, 2017, 107, 893-899.	2.7	37
36	Race/Ethnicity and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2017, 69, 1823-1831.	5.6	70

MICHAEL A FISCHER

#	Article	IF	CITATIONS
37	Physician assessments of drug seeking behavior: A mixed methods study. PLoS ONE, 2017, 12, e0178690.	2.5	8
38	Persistent opioid use following cesarean delivery: patterns and predictors among opioid-naÃ ⁻ ve women. American Journal of Obstetrics and Gynecology, 2016, 215, 353.e1-353.e18.	1.3	220
39	Academic Detailing in Diabetes: Using Outreach Education to Improve the Quality of Care. Current Diabetes Reports, 2016, 16, 98.	4.2	13
40	Key Features of Academic Detailing: Development of an Expert Consensus Using the Delphi Method. American Health and Drug Benefits, 2016, 9, 42-50.	0.5	32
41	A Randomized Telephone Intervention Trial to Reduce Primary Medication Nonadherence. Journal of Managed Care & Specialty Pharmacy, 2015, 21, 124-131.	0.9	23
42	Chronic hypertension in pregnancy and the risk of congenital malformations: a cohort study. American Journal of Obstetrics and Gynecology, 2015, 212, 337.e1-337.e14.	1.3	63
43	Characteristics of Academic Detailing: Results of a Literature Review. American Health and Drug Benefits, 2015, 8, 414-22.	0.5	19
44	Knowing the Previously Unknown. Medical Care, 2014, 52, 767-769.	2.4	2
45	Pharmacy-based Interventions to Reduce Primary Medication Nonadherence to Cardiovascular Medications. Medical Care, 2014, 52, 1050-1054.	2.4	40
46	Chipping Away. JAMA Internal Medicine, 2013, 173, 44.	5.1	2
47	Academic Detailing Can Play A Key Role In Assessing And Implementing Comparative Effectiveness Research Findings. Health Affairs, 2012, 31, 2206-2212.	5.2	42
48	Trouble Getting Started: Predictors of Primary Medication Nonadherence. American Journal of Medicine, 2011, 124, 1081.e9-1081.e22.	1.5	133
49	Primary Medication Non-Adherence: Analysis of 195,930 Electronic Prescriptions. Journal of General Internal Medicine, 2010, 25, 284-290.	2.6	465
50	Primary Non-adherence to Prescribed Medications. Journal of General Internal Medicine, 2010, 25, 765-765.	2.6	0
51	Uptake of Electronic Prescribing in Community-Based Practices. Journal of General Internal Medicine, 2008, 23, 358-363.	2.6	38
52	Prior authorization for biologic diseaseâ€modifying antirheumatic drugs: A description of US medicaid programs. Arthritis and Rheumatism, 2008, 59, 1611-1617.	6.7	14
53	Effect of Electronic Prescribing With Formulary Decision Support on Medication Use and Cost. Archives of Internal Medicine, 2008, 168, 2433.	3.8	93
54	Restrictions on Antidepressant Medications for Children: A Review of Medicaid Policy. Psychiatric Services, 2007, 58, 135-138.	2.0	5

MICHAEL A FISCHER

#	Article	IF	CITATIONS
55	Nononcologic Use of Human Recombinant Erythropoietin Therapy in Hospitalized Patients. Archives of Internal Medicine, 2007, 167, 840.	3.8	8
56	The National e-Prescribing Patient Safety Initiative. Drug Safety, 2007, 30, 461-464.	3.2	3
57	Prior Authorization Policies for Selective Cyclooxygenase-2 Inhibitors in Medicaid. Medical Care, 2006, 44, 658-663.	2.4	6
58	The Hepatotoxicity of Antifungal Medications in Bone Marrow Transplant Recipients. Clinical Infectious Diseases, 2005, 41, 301-307.	5.8	59
59	Economic Implications of Evidence-Based Prescribing for Hypertension. JAMA - Journal of the American Medical Association, 2004, 291, 1850.	7.4	162
60	Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit. Pharmacoepidemiology and Drug Safety, 2004, 13, 207-214.	1.9	45
61	An Algorithmic Computerised Order Entry Approach to Assist in the Prescribing of New Therapeutic Agents. Drug Safety, 2004, 27, 1253-1261.	3.2	9
62	Economic Consequences of Underuse of Generic Drugs: Evidence from Medicaid and Implications for Prescription Drug Benefit Plans. Health Services Research, 2003, 38, 1051-1064.	2.0	68
63	Conversion From Intravenous to Oral Medications. Archives of Internal Medicine, 2003, 163, 2585.	3.8	64